Failure with HCV DAA regimen in a high volume treatment center under real life conditions
J Petersen, K Wursthorn, K Olah, T Lorenzen, A Plettenberg, S Unger, C Czaja-Harder, K Matschenz, A Stoehr, P Buggisch · Zeitschrift für Gastroenterologie · 2016 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: HCV DAA therapies yielded SVR12 rates of more than 90% in randomized clinical trials. Given this remarkable efficacy, understanding factors associated with treatment failures in real-world clincal practice remains challenging due to the relatively small number of patients who do not achieve SVR. Aim: To examine a large number of patients from an experienced high volume treatment center of ID physicians and hepatologists selecting patients conjointly for HCV treatment to assess the characteristics of patients who failed available DAA therapies since licensing in mid 2014. Methods: Data were collected…
